References
- Open Government Data. Prevalence of Diabetes. Global report on diabetes. Geneva: World Health Organization, 2016
- Health Promotion Administration, Ministry of Health and Welfare, DATA.GOV.TW, Diabetes mellitus prevalence. Available at: http://data.gov.tw/node/9337 [Last accessed 12 June 2017]
- Dieren SV, Beulens JWJ, Schouw YTVD, et al. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010;17(Suppl 1):S3-S8
- Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health 2001;4:392-400
- Mngomezulu N, Yang CC. Quality of life and its correlates in diabetic outpatients in Swaziland. Int Health 2015;7:464-71
- Trikkalinou A, Papazafiropoulou AK, Melidonis A. Type 2 diabetes and quality of life. World J Diabetes 2017;8:120-9
- Kennedy-Martin T, Mitchell BD, Boye KS, et al. The health technology assessment environment in mainland China, Japan, South Korea, and Taiwan – implications for the evaluation of diabetes mellitus therapies. Value Health Regional Issues 2014;3:108-16
- Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes, 4th edn. New York: Oxford University Press, 2015
- Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res 2015;15:496
- Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. Diabet Med 2015;32:890-8
- Lafeuille MH, Grittner AM, Gravel J, et al. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control. J Med Econ 2014;18:113-25
- Sabale U, Ekman M, Granstrom O, et al. Cost-effectiveness of dapagliflozin (Forxiga) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes 2015;9:39-47
- van Haalen HG, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig 2014;34:135-46
- Froberg DG, Kane RL. Methodology for measuring health-state preferences – I: Measurement strategies. J Clin Epidemiol 1989;42:345-54
- Harris SB, Khunti K, Landin-Olsson M, et al. Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Pref Adher 2013;16:925-36
- Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013;3:90
- Sullivan SD, Devine EB, Hakim Z, et al. Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics 2002;20:1079-89
- Davies EW, Matza LS, Worth G, et al. Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health Qual Life Outcomes 2015;13:90
- Huang ES, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care 2007;30:2478-83
- Fenwick E, Rees G, Pesudovs K, et al. Social and emotional impact of diabetic retinopathy: a review. Clin Exp Ophthalmol 2012;40:27-38
- Gage BF, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;9:1829-36
- Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res 1994;29:207-24
- Patrick DL, Starks HE, Cain KC, et al. Measuring preferences for health states worse than death. Med Decis Making 1994;14:9-18
- Hsin DH, Macer D. Comparisons of life images and end-of-life attitudes between the elderly in Taiwan and New Zealand. J Nurs Res 2006;14:198-208
- Harrsion JD, Young JM, Butow P, et al. Is it worth the risk? A systematic review of instruments that measure risk propensity for use in the health setting. Soc Sci Med 2005;60:1385-96
- Lin MR, Yu WY, Wang SC. Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury. Arch Phys Med Rehabil 2012;93:245-52